A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698 · Recruiting

Last updated 2026-05-28

This study is testing different doses of the medicine NNC0519-0130 to see how well it can reduce kidney damage in adults with chronic kidney disease.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 465 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-12 · est. completion 2026-09

Where 147 sites · Argentina, Australia, Brazil, Bulgaria, Czechia, India, Italy, Japan, Malaysia, Poland, South Korea, Spain, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT06717698 ↗

Description as written by the study sponsor.

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.

Treatments tested

NNC0519-0130 Drug

NNC0519-0130 will be administered subcutaneously.
Placebo Drug

Placebo matching NNC0519-0130 will be administered subcutaneously.
Semaglutide Drug

Semaglutide will be administered subcutaneously.

Main thing measured	Change in urinary albumin-to-creatinine ratio (UACR) at week 12
Sponsor	Novo Nordisk A/S
Conditions studied	Chronic Kidney Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06717698 ↗